Accustem Sciences Inc. (ACUT): Total Liabilities
$4.95M
As of 2025-12-31
$5.72M
As of 2026-06-30
+66.2%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.95M | +47.2% | 2026-04-14, Balance as of period end |
| 2024-12-31 | $3.36M | +49.8% | 2026-04-14, Balance as of period end |
| 2023-12-31 | $2.25M | +108.1% | 2025-04-03, Balance as of period end |
| 2022-12-31 | $1.08M | +53.6% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $702.7K | n/a | 2023-02-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Accustem Sciences Inc. (ACUT) | 2025-12-31 | $4.95M | +47.2% |
| Semnur Pharmaceuticals, Inc. (SMNR) | 2025-12-31 | $22.10M | -55.3% |
| Aspire Biopharma Holdings, Inc. (ASBP) | 2025-12-31 | $7.69M | +355.5% |
| Alzamend Neuro, Inc. (ALZN) | 2026-04-30 | $1.35M | +112.1% |
| NeuroSense Therapeutics Ltd. (NRSN) | 2025-12-31 | $2.59M | +29.9% |
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $3.80M | +2.5% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $5.08M | -14.4% |
| Ocean Biomedical, Inc. (OCEA) | 2024-12-31 | $98.52M | n/a |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $754.4K | +74.3% |
Compare ACUT, SMNR, ASBP, ALZN side by side · Screen every company in Pharmaceutical Preparations ↗